Certain chemotherapy combinations work best

LONDON (Reuters) - Greek researchers have identified the chemotherapy combinations that appear to help women with advanced breast cancer live longest, they reported Tuesday.

Women who took a combination of a taxane-based therapy such as Taxol or paclitaxel, or Sanofi Aventis’s Taxotere, known generically as docetaxel, with other drugs lived a year longer than women who did not get chemotherapy.

Women given either a single taxane drug or a combination that included an anthracycline such as Adriamycin with older chemotherapy drugs lived an extra eight months compared to untreated women, said John Ioannidis of the University of Ioannina School of Medicine in Greece.

The findings are the first to compare different chemotherapy treatments used over the past 35 years to gauge how effective they are, he added.

“The main message is this is one type of cancer where we do have a number of treatments that are effective, said Ioannidis, who led the study published in the Journal of the National Cancer Institute.

“What is new is the quantification and being able to put a number on how much is the benefit for what is available,” Ioannidis told Reuters in a telephone interview.

Breast cancer is the leading cause of cancer death among women worldwide, according to the American Cancer Society. The group estimates about 465,000 women died of breast cancer worldwide in 2007 and 1.3 million new cases were diagnosed.

Declining death rates from the disease in developed countries have been attributed to early detection through mammography screening and to improved treatment.

One widespread treatment is the generic pill tamoxifen, which blocks estrogen from fuelling tumors. Another treatment that targets hormones is a class of drugs called aromatase inhibitors such as AstraZeneca Plc’s Arimidex.

Ioannidis and his team analyzed 128 clinical trials involving more than 26,000 women who received chemotherapy drugs which kill cancer cells directly rather than target hormones. The review included 148 comparisons of different treatments.

The findings are also a step toward finding consensus on the best dosage, timing and sequence or combination of different treatments, the researchers added.

(Reporting by Michael Kahn; Editing by Maggie Fox and Jon Loades-Carter)


Related Posts:

By Michael Kahn LONDON (Reuters) - Many genes linked to various cancers do not appear to raise the risk of getting cancer after all, according to an analysis of hundreds of studies published on Tuesday. The findings highlight the need to exercise caution over the increasing number of studies associating common genetic variations with a range of

Full Post: Many studies needed to tie genes to cancer: study

By Karla Gale NEW YORK (Reuters Health) - Freezing embryos before undergoing cancer treatment that may cause infertility is as successful for women with cancer as it is for women without cancer, new study findings indicate. The investigators, who presented their findings this week at the 64th annual meeting of the American Society of Reproductive Medicine in

Full Post: Embryo preservation often works for cancer patients

LONDON (Reuters) - The most commonly used breast cancer drug may cause tumors to spread in a small number of women with low levels of a protein which makes cells stick together, British researchers said on Thursday. The findings could lead to new tests to determine which women are not likely to benefit from tamoxifen and

Full Post: Study sheds light on breast cancer drug failure

LONDON (Reuters) - Britain’s healthcare cost effectiveness watchdog NICE has rebuffed GlaxoSmithKline’s latest bid to get its drug Tyverb - for women with advanced breast cancer - into the state health system, the company said on Tuesday. Glaxo said as part of the ongoing appeal it had offered to run a 12-week trial in women with

Full Post: UK’s NICE turns down Glaxo Tyverb offer

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - The lung cancer pill Iressa has shown surprising results for patients with advanced disease where it has been at least as effective as a standard chemotherapy treatment, researchers reported on Thursday. Patients who got the once-a-day pill made by AstraZeneca lived as long as those given the

Full Post: Lung cancer pill may get second chance after tests

Site Navigation

Most Read



  • kinwrite.com@gmail.com